A Phase IIB Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1A (Cromolyn) as an Adjuvant Treatment in Subjects With Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.
• Diagnosis of ALS; the diagnosis of ALS defined by revised El Escorial criteria as follows:
∙ Evidence of lower motor neuron (LMN) degeneration by clinical, electrophysiological, or neuropathological examination.
‣ Evidence of upper motor neuron (UMN) degeneration by clinical examination.
‣ Progressive spread of symptoms or signs within a region or to other regions, as determined by clinical examination or the history of disease progression.
‣ Absence of electrophysiological, neuroimaging, or pathological evidence of other diseases that might explain the UMN or LMN degeneration and exclusion of other causes.
• Male or female subjects aged 18 to 75 years inclusive.
• Must provide written informed consent for study-related procedures.
• Must be capable of completing all study-related procedures, assessments, and visits in the judgment of Investigator.
• Disease duration from ALS symptom onset of motor weakness ≤24 months.
• ALSFRS-R total score ≥38 at screening visit.
• ALSFRS-R Breathing subscore should be ≥9 at the time of screening.
• ALSFRS-R Bulbar subscore should be ≥9 at the time of screening.
• Forced vital capacity \>70% of predicted value.
⁃ PIFR ≥100 L/minute.
⁃ Must be receiving a stable dose of standard-of-care treatment Riluzole for 4-weeks before signing informed consent.
⁃ Female subjects who are of childbearing potential must agree to use of highly effective methods of contraception consistent with local regulations during the study, and for 3 months after the study drug administration. Examples include the following, but not limited to:
• Combined (estrogen and progestogen containing) or progestogen-only hormonal contraceptives;
∙ Intrauterine device or intrauterine hormone-releasing system; OR
∙ Post-menopausal status must have experienced their last menstrual period minimum of 1 year prior to study drug administration; OR
∙ Surgically sterilized. Female subject should be willing to not donate egg during the trial and for 3 months after the last dose of the study drug.
⁃ Male subjects who are sexually active with a female of childbearing potential must agree to use highly effective contraception as described above, or a combination of 2 acceptable methods of contraception (e.g., a barrier method along with a female partner using a hormonal contraceptive method), in accordance with local regulations, throughout the duration of the study, and for 3 months after the last dose of the study drug.
⁃ (Male subject should be willing to not donate sperm during the trial and for 3 months after the last dose of the study drug.)